New oral drug trial aims to help older adults with bone marrow disorder
NCT ID NCT07616336
First seen Jun 11, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This phase 2 trial tests the drug chidamide (Tucidinostat) in 15 older adults (60+) with intermediate-to-high-risk myelodysplastic syndromes, a bone marrow disorder that can lead to leukemia. Participants take chidamide orally twice a week for up to 3 months, with 6 months of follow-up. The study will measure how many people respond to treatment and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital (Xiamen), Fudan University
Xiamen, Fujian, 361015, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chidamide (also called Tucidinostat), an oral drug
What this could lead to
If it works, this could point toward a new treatment option for older patients with myelodysplastic syndromes who have few alternatives.
What could go wrong
This is a very small, early-phase trial with only 15 people. It may not show enough benefit or could have side effects that limit its use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.